Stephen G. Divers
The US Oncology Network · 37 works · 1,884 citations · h-index 10
Top works
- Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
- Informed Consent for Clinical Trials: a Comparative Study of Standard Versus Simplified Forms
- Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
- Cell surface expression of lysosome‐associated membrane protein‐2 (lamp2) and CD63 as markers ofin vivoplatelet activation in malignancy
- Quantitation of CD62, soluble CD62, and lysosome‐associated membrane proteins 1 and 2 for evaluation of the quality of stored platelet concentrates
- Scurvy: An often forgotten cause of bleeding
- Acute transient leukopenia as a sign of TRALI
- Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer
- Phase I/IIa Study of Cisplatin and Gemcitabine As Induction Chemotherapy Followed by Concurrent Chemoradiotherapy With Gemcitabine and Paclitaxel for Locally Advanced Non–Small-Cell Lung Cancer
- Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy
- Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.
- Phase II study of sagopilone (ZK-Epo) in patients with recurrent metastatic breast cancer (MBC)
- Abstract 921: Identification of NRG1 fusions in patients with solid tumors: analysis from a real-world community oncology network
- Abstract 4460: Clinical utility of comprehensive cell-free DNA (cfDNA) analysis to identify genomic biomarkers in newly diagnosed metastatic non-small cell lung cancer (mNSCLC)
- Operationalizing Weight-Based Dosing of Pembrolizumab: Opportunities and Challenges
- Abstract CT151: G1T28, a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin for extensive stage small cell lung cancer (ES-SCLC): preliminary results
- Data from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
- Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.
- Clinical and molecular presentation of KRAS G12D-mutated pancreatic ductal adenocarcinoma in real-world settings.
- Minimum episode volume to reduce stochastic risk in the Enhancing Oncology Model.